Feasibility study of storage concepts for Scout and other NASA solid propellant launch vehicles

Feasibility study of long term storing of Scout and other solid propellant launch vehicles in assembled, flightworthy configuration and facility requirement

Status, Dispersal, and Breeding Biology of the Exotic Eurasian Collared-Dove (Streptopelia decaocto) in Arkansas

The exotic Eurasian Collared-Dove (Streptopelia decaocto) was first sighted in Arkansas at Harrison (Boone Co.) on 25 June 1989. Since this initial sighting the species has grown in numbers and is now present in 42 of 75 counties across the state. In the spring and summer of 2009 and 2010, 20 nests were observed in the urban areas of Fort Smith (Sebastian County). Fifteen of the 20 nests (75%) were located on human-made structures of which 13 (65%) were on an electrical substation and two (10%) were on utility poles. The remaining 5 nests (25%) were in trees. Mean nest height was 7.62 m (n = 20 nests), and the mean width of the nest site support was 40 cm (n = 6 nests). Thirteen of the 20 nests (65%) yielded fledgling(s). Three focal nests were chosen for intense observation. Nest building lasted 1 to 3 days (mean = 2 days); incubation period was 15 days; and fledging occurred 17-18 days after hatching (n = 3 nests). A total of 6 young fledged from these 3 nests

Satellite monitoring of sea surface pollution

There are no author-identified significant results in this report

Information Security as Strategic (In)effectivity

Security of information flow is commonly understood as preventing any information leakage, regardless of how grave or harmless consequences the leakage can have. In this work, we suggest that information security is not a goal in itself, but rather a means of preventing potential attackers from compromising the correct behavior of the system. To formalize this, we first show how two information flows can be compared by looking at the adversary's ability to harm the system. Then, we propose that the information flow in a system is effectively information-secure if it does not allow for more harm than its idealized variant based on the classical notion of noninterference

Birth registration and children's rights: a complex story

Birth registration is a fundamental right of all children and a basic function of all modern governments. So, given the extensive anticipated benefits of birth registration, there has been increasing interest from development organisations in implementing programmes on birth registration in countries with low rates of registration.But there is a significant lack of empirical research that explores the effects of birth registration, and if and how it benefits children in practice.Plan’s new research in India, Kenya, Sierra Leone and Vietnam reveals the results of an investigation into the impact of birth registration. What emerges is a complex picture of the interrelationship between children’s rights and birth registration. As a result, the report makes a series of important recommendations for governments and development partners

Complete Sequence of pSAM7, an IncX4 Plasmid Carrying a Novel bla[sub]CTX-M-14b Transposition Unit Isolated from ' Escherichia coli ' and ' Enterobacter cloacae ' from cattle

The same plasmid carrying blaCTX-M-14b was identified from an Escherichia coli isolate and an Enterobacter cloacae isolate collected from cattle in the United Kingdom by complete plasmid sequencing. This 35,341-bp plasmid, pSAM7, had an IncX4 backbone that is 99% identical to that of pJIE143 from a human isolate in Australia. PCR screening identified pSAM7-like plasmids in three other E. coli isolates of different multilocus sequence types isolated from cattle on different farms in the United Kingdom

The Prevalence of Spent Lead Shot in Wetland Sediments and Ingested by Wild Ducks in Coastal Queensland

Ingestion of spent lead shot by waterfowl, leading to lead poisoning, has been recorded in many parts of the world. In Australia, most attention has been in the southern states where hunting is more popular than elsewhere, and the assumption has been that, except for a few places, the prevalence of lead poisoning is low. To test this assumption, we collected digestive tracts of ducks from four localities and sediments from two wetlands in coastal Queensland where hunting occurs, but where there has been no suggestion that large numbers of birds may be exposed to the possibility of ingesting lead. We found a high prevalence of lead shot in the gut and sediment samples, suggesting that large numbers of birds may be at risk of lead poisoning, and that the prevalence is greater than the state prescribed threshold which would trigger a ban on the use of lead shot at some wetlands

Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial

BACKGROUND: Despite increasing worldwide use of anti-vascular endothelial growth factor agents for treatment of retinopathy of prematurity (ROP), there are few data on their ocular efficacy, the appropriate drug and dose, the need for retreatment, and the possibility of long-term systemic effects. We evaluated the efficacy and safety of intravitreal ranibizumab compared with laser therapy in treatment of ROP. METHODS: This randomised, open-label, superiority multicentre, three-arm, parallel group trial was done in 87 neonatal and ophthalmic centres in 26 countries. We screened infants with birthweight less than 1500 g who met criteria for treatment for retinopathy, and randomised patients equally (1:1:1) to receive a single bilateral intravitreal dose of ranibizumab 0·2 mg or ranibizumab 0·1 mg, or laser therapy. Individuals were stratified by disease zone and geographical region using computer interactive response technology. The primary outcome was survival with no active retinopathy, no unfavourable structural outcomes, or need for a different treatment modality at or before 24 weeks (two-sided α=0·05 for superiority of ranibizumab 0·2 mg against laser therapy). Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, NCT02375971. INTERPRETATION: Between Dec 31, 2015, and June 29, 2017, 225 participants (ranibizumab 0·2 mg n=74, ranibizumab 0·1 mg n=77, laser therapy n=74) were randomly assigned. Seven were withdrawn before treatment (n=1, n=1, n=5, respectively) and 17 did not complete follow-up to 24 weeks, including four deaths in each group. 214 infants were assessed for the primary outcome (n=70, n=76, n=68, respectively). Treatment success occurred in 56 (80%) of 70 infants receiving ranibizumab 0·2 mg compared with 57 (75%) of 76 infants receiving ranibizumab 0·1 mg and 45 (66%) of 68 infants after laser therapy. Using a hierarchical testing strategy, compared with laser therapy the odds ratio (OR) of treatment success following ranibizumab 0·2 mg was 2·19 (95% Cl 0·99-4·82, p=0·051), and following ranibizumab 0·1 mg was 1·57 (95% Cl 0·76-3·26); for ranibizumab 0·2 mg compared with 0·1 mg the OR was 1·35 (95% Cl 0·61-2·98). One infant had an unfavourable structural outcome following ranibizumab 0·2 mg, compared with five following ranibizumab 0·1 mg and seven after laser therapy. Death, serious and non-serious systemic adverse events, and ocular adverse events were evenly distributed between the three groups. FINDINGS: In the treatment of ROP, ranibizumab 0·2 mg might be superior to laser therapy, with fewer unfavourable ocular outcomes than laser therapy and with an acceptable 24-week safety profile. FUNDING: Novartis

Compliance with occlusion therapy for childhood amblyopia

Purpose. Explore compliance with occlusion treatment of amblyopia in the Monitored and Randomized Occlusion Treatment of Amblyopia Studies (MOTAS and ROTAS), using objective monitoring. Methods. Both studies had a three-phase protocol: initial assessment, refractive adaptation, and occlusion. In the occlusion phase, participants were instructed to dose for 6 hours/day (MOTAS) or randomized to 6 or 12 hour/day (ROTAS). Dose was monitored continuously using an occlusion dose monitor (ODM). Results. One hundred and fifty-two patients (71 male, 81 female; 122 Caucasian, 30 non-Caucasian) of mean ± SD age 68 ± 18 months participated. Amblyopia was defined as an interocular acuity difference of at least 0.1 logMAR and was associated with anisometropia in 50, strabismus in 44, and both (mixed) in 58. Median duration of occlusion was 99 days (interquartile range 72 days). Mean compliance was 44%, mean proportion of days with no patch worn was 42%. Compliance was lower (39%) on weekends compared with weekdays (46%, P = 0.04), as was the likelihood of dosing at all (52% vs. 60%, P = 0.028). Compliance was lower when attendance was less frequent (P < 0.001) and with prolonged treatment duration (P < 0.001). Age, sex, amblyopia type, and severity were not associated with compliance. Mixture modeling suggested three subpopulations of patch day doses: less than 30 minutes; doses that achieve 30% to 80% compliance; and doses that achieve around 100% compliance. Conclusions. This study shows that compliance with patching treatment averages less than 50% and is influenced by several factors. A greater understanding of these influences should improve treatment outcome. (ClinicalTrials.gov number, NCT00274664.